Human Liver S9 Fraction

View Products

PackagingCharacterization ProvidedProduct DetailsSafety, Handling, and Storage

 

S9 contains a wide variety of enzymes catalyzed by hydrolysis, reduction, oxidation and conjugation, including P450 enzymes, flavin-mono­oxygenases, carboxyl­esterases, epoxide hydrolase, UDP-glucuronosyl­transferases, sulfotransferases, methyl­transferases, acetyl­trans­ferases, gluta­thione S-trans­fer­ases and other drug-metabolizing enzymes.

View available lot and characterization data here!

Packaging

Concentration: 20 mg/mL
Suspension buffer: 50 mM TRIS·HCl (pH 7.4 at 4°C) containing 150 mM KCl and 2 mM EDTA

Characterization Provided

• Specific content of cytochrome b5
• NADPH-cytochrome c reductase activity
• CYP: 7-Ethoxycoumarin O-dealkylation
• UGT: 4-Methylumbelliferone glucuronidation
• GST: 1-Chloro-2,4-dinitro-benzene (CDNB)
• Donor information, including age, ethnicity, gender, cause of death, and infectious disease status

Product Details

• XTreme 200 Pooled Human Liver S9
  • 100 male/100 female 
  • Large lots with reserve tissue from all 200 donors allow long-term availability
  • Same donor pool as our XTreme 200 human liver microsomes
  • Offered in bulk amounts
    • 5 mL at 20 mg/mL
    • 50 mL at 20 mg/mL
  • Intended for in vitro Phase 1 and Phase 2 metabolism studies

• Pooled Human Liver S9
  • At least 50 donors
  • Pooled irrespective of gender or racial back­ground
  • Each sample significantly (but not necessarily equally) repre­sented in the pool
  • Offered in bulk amounts
    • 5 mL at 20 mg/mL
    • 50 mL at 20 mg/mL
  • Intended for in vitro Phase 1 and Phase 2 metabolism studies

• Pooled Male Human Liver S9
  • At least 10 male donors
  • Pooled irrespective of racial back­ground
  • Each sample significantly (but not necessarily equally) represented in the pool
  • Intended for in vitro Phase 1 and Phase 2 metabolism studies of gender differences in drug metabolism

• Pooled Female Human Liver S9
  • At least 10 female donors
  • Pooled irrespective of racial background
  • Each sample significantly (but not necessarily equally) represented in the pool
  • Intended for in vitro Phase 1 and Phase 2 metabolism studies of gender differences in drug metabolism

Safety, Handling, and Storage

Informed Consent Statement

A single organization regulates and oversees the use of human tissue intended for transplantation in the United States, namely the United Network for Organ Sharing (UNOS). Organ donors may elect to have their organs used either for transplantation only, or for transplantation or research. Thus, the donor (or the donor's family) has the right to prevent the use of the donor's organs for research. Regardless of the use of donated organs, no compensation is given to the donor’s family; any such compensation is illegal in the United States. In those cases where donors (or family members) elect to withhold organs from research uses, any organs that cannot be transplanted are discarded.

XenoTech receives hepatic, renal, intestinal, pulmonary, and other human tissue from various regional organ procurement organizations (OPOs) that obtain organs approved for research use. Regulations in the United States require that, regardless whether the organ is intended for transplantation or research purposes, the organ donor's identity be treated as highly confidential information. Organ procurement organizations maintain the informed consent records from each donor, and our Standard Operating Procedure requires that XenoTech personnel confirm the existence of informed consent for research purposes, prior to transport of organs to XenoTech. This procedure is intended to ensure that XenoTech manufactures human-derived products only when informed consent has been granted for research use of those specific organs. XenoTech does not, and, in consideration of confidentiality, cannot obtain the informed consent records from these organizations.

All human tissue accepted by XenoTech has been tested for the possible presence of various infectious diseases, and XenoTech does not accept human-derived material unless the donor has tested negative (non-reactive) for RPR, HIVAb, HTLVAb, HBsAg and HCVAb. All human tissue is also tested for CMVAb.  However, due to the widespread (nearly ubiquitous) appearance of CMV in the population, and its relative insignificance as an infectious agent, tissues from donors reactive for CMVAb are accepted.  The serology status of each donor is typically determined by ELISA by the organ procurement hospital.

XenoTech does not deal directly with - nor does it make any direct payments to - the surgeons who procure organs or the medical institutions where they work.

Caution

In the case of human tissue, XenoTech accepts only non-transplantable tissue from donors who test negative for HIV 1 and 2, HTLV, and Hepatitis B and C. However, as a precaution, all human-de­rived samples should be regarded as a potential bio­hazard and should be stored, handled and discarded accordingly. Cellular and subcellular fractions are intended for in vitro use only.

Products

Product #	Name	Gender	Amount
H0610.S9	Pooled Human Liver S9 Fraction	Mixed	0.5 mL at 20 mg/mL
H0620.S9	Pooled Human Liver S9 Fraction	Mixed	1.0 mL at 20 mg/mL
H0630.S9	Pooled Human Liver S9 Fraction	Mixed	5.0 mL at 20 mg/mL
H0640.S9	Pooled Human Liver S9 Fraction	Mixed	50 mL at 20 mg/mL
H1000.S9	Pooled Human Liver S9 Fraction	Male	1.0 mL at 20 mg/mL
H1500.S9	Pooled Human Liver S9 Fraction	Female	1.0 mL at 20 mg/mL
H2610.S9	XTreme 200 Pooled Human Liver S9 Fraction	Mixed	0.5 mL at 20 mg/mL
H2620.S9	XTreme 200 Pooled  Human Liver S9 Fraction	Mixed	1.0 mL at 20 mg/mL
H2630.S9	XTreme 200 Pooled Human Liver S9 Fraction	Mixed	5.0 mL at 20 mg/mL
H2640.S9	XTreme 200 Pooled Human Liver S9 Fraction	Mixed	50 mL at 20 mg/mL